Other languages Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 06:35:11 2024-04-30 am EDT			5-day change	1st Jan Change
2.7 ^ILa	+3.85%		+3.85%	+3.85%

Apr. 03	Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	CI
Mar. 28	Can-Fite Biopharma Ltd. Announces Clinical Update	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	Apr. 03
Can-Fite Biopharma Ltd. Announces Clinical Update	Mar. 28
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs	Mar. 11
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office	Feb. 28
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	Jan. 30
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial	Jan. 29
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action	Dec. 20
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	Dec. 18
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson	Dec. 18
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients	Dec. 04
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 30
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	Nov. 21
Top Midday Gainers	Nov. 21
Can-Fite Biopharma Reports 'Complete Response' in Liver Cancer Patient Treated With Namodenoson	Nov. 21
Top Premarket Gainers	Nov. 21
Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson	Nov. 21
Can-Fite Biopharma Ltd. Provides Business Update	Nov. 01
Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal	23-10-30
Can-Fite Biopharma Ltd. Enters into an Agreement with Collaborations Pharmaceuticals Inc to Develop Anti-Cancer Drugs Utilizing Artificial Intelligence	23-10-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Other languages

Filters